Socialist Party deputy Juan Luis Castro has revealed his growing suspicions regarding possible price-fixing between several laboratories across the country, representing much of Chile’s pharmaceutical industry. The congressman has pointed to a 42% increase in the prices of 16 of the country’s 20 most-used medications, all during a short period between 2015 and 2016.
Castro, who is a member of the Health Commission, believes that “this increase in the price of 20 of Chile’s most consumed medications is a low blow to the middle class and all popular sectors, since it implies increases in common remedies such as paracetamol, ibuprofen, loratadine, salbutamol and many other daily-use substances.”
Castro announced his intentions to “take these findings to the Public Health Institute and the National Economic Prosecutor, because there probably are signs of collusion, agreements to raise prices in their products, as has already been seen with drugstores and which may now be occurring between laboratories.”
Full Content: Terra
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Subscribers Defend $4.7 Billion Antitrust Verdict Against NFL in Court Filings
Jul 19, 2024 by
CPI
Von der Leyen Calls for Competition Policy to Boost EU Companies’ Growth
Jul 19, 2024 by
CPI
Vermont AG Sues Pharmacy Benefit Managers Over Drug Prices
Jul 18, 2024 by
CPI
Australians Face Increased Stamp Prices Following ACCC Approval
Jul 18, 2024 by
CPI
Live Nation Seeks Dismissal of DOJ Antitrust Allegations
Jul 18, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Private Equity Roll-Up Schemes
Jun 28, 2024 by
CPI
The FTC’s Focus on Private Equity is Warranted
Jun 28, 2024 by
CPI
Unraveling the Roll-Up: Private Equity’s Misunderstood Investment Strategy
Jun 28, 2024 by
CPI
Antitrust Focus on Private Equity Funds and Serial Acquisitions
Jun 28, 2024 by
CPI
Private Equity Roll-Ups Amidst Heightened Antitrust Enforcement
Jun 28, 2024 by
CPI